CURIS, INC. (CRIS) Operating Margin
- Operating margin · 12 months: Value -203.15%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -203.15% | Operating income / revenue. Period ending 2026-06-30. $-8.76M ÷ $4.31M × 100 ≈ -203.15% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -8.76M USD | Operating Income (Loss) |
| Revenue | 4.31M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-8.76M | $4.31M | (m) | (m) | (m) | -203.15% |
| 2026-03-31 | $-7.08M | $7.06M | (m) | (m) | (m) | -100.17% |
| 2025-12-31 | $-5.71M | $9.44M | (m) | (m) | (m) | -60.50% |
| 2025-09-30 | $-34.33M | $11.65M | (m) | (m) | (m) | -294.64% |
| 2025-06-30 | $-37.97M | $11.40M | (m) | (m) | (m) | -332.92% |
| 2025-03-31 | $-42.23M | $11.20M | (m) | (m) | (m) | -376.99% |
| 2024-12-31 | $-44.54M | $10.91M | (m) | (m) | (m) | -408.34% |
| 2024-09-30 | $-47.75M | $10.26M | (m) | (m) | (m) | -465.42% |
| 2024-06-30 | $-49.55M | $10.16M | (m) | (m) | (m) | -487.63% |
| 2024-03-31 | $-49.17M | $9.81M | (m) | (m) | (m) | -501.16% |
| 2023-12-31 | $-48.33M | $10.02M | (m) | (m) | (m) | -482.21% |
| 2023-09-30 | $-46.35M | $10.21M | (m) | (m) | (m) | -453.82% |
| 2023-06-30 | $-46.59M | $10.21M | (m) | (m) | (m) | -456.51% |
| 2023-03-31 | $-49.51M | $10.40M | (m) | (m) | (m) | -476.00% |
| 2022-12-31 | $-53.02M | $10.16M | (m) | (m) | (m) | -521.75% |
| 2022-09-30 | $-55.37M | $10.41M | (m) | (m) | (m) | -531.86% |
| 2022-06-30 | $-52.81M | $10.62M | (m) | (m) | (m) | -497.07% |
| 2022-03-31 | $-48.40M | $10.52M | (m) | (m) | (m) | -460.19% |
| 2021-12-31 | $-42.06M | $10.65M | (m) | (m) | (m) | -395.01% |
| 2021-09-30 | $-35.77M | $10.54M | (m) | (m) | (m) | -339.47% |
| 2021-06-30 | $-30.43M | $10.24M | (m) | (m) | (m) | -297.16% |
| 2021-03-31 | $-25.22M | $10.31M | (m) | (m) | (m) | -244.46% |
| 2020-12-31 | $-24.90M | $10.84M | (m) | (m) | (m) | -229.79% |
| 2020-09-30 | $-25.96M | $11.10M | (m) | (m) | (m) | -233.89% |
| 2020-06-30 | $-26.57M | $11.21M | (m) | (m) | (m) | -237.00% |
| 2020-03-31 | $-27.28M | $10.95M | (m) | (m) | (m) | -249.22% |
| 2019-12-31 | $-24.36M | $10.00M | (m) | (m) | (m) | -243.46% |
| 2019-09-30 | $-22.17M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-23.26M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-24.98M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-29.33M | $10.43M | (m) | (m) | (m) | -281.29% |
| 2018-09-30 | $-31.31M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-39.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-44.62M | $10.23M | (m) | (m) | (m) | -435.91% |
| 2017-12-31 | $-49.76M | $9.90M | (m) | (m) | (m) | -502.73% |
| 2017-09-30 | $-53.40M | $9.00M | (m) | (m) | (m) | -593.41% |
| 2017-06-30 | $-66.71M | $8.31M | (m) | (m) | (m) | -802.51% |
| 2017-03-31 | $-64.28M | $7.93M | (m) | (m) | (m) | -810.45% |
| 2016-12-31 | $-58.04M | $7.53M | (m) | (m) | (m) | -771.08% |
| 2016-09-30 | $-60.52M | $7.26M | (m) | (m) | (m) | -833.93% |
| 2016-06-30 | $-37.58M | $7.54M | (m) | (m) | (m) | -498.14% |
| 2016-03-31 | $-34.27M | $7.95M | (m) | (m) | (m) | -431.24% |
| 2015-12-31 | $-56.48M | $7.88M | (m) | (m) | (m) | -716.91% |
| 2015-09-30 | $-48.05M | $7.78M | (m) | (m) | (m) | -617.67% |
| 2015-06-30 | $-47.96M | $7.50M | (m) | $9.18M | (m) | -639.54% |
| 2015-03-31 | $-42.13M | $10.22M | (m) | (m) | (m) | -412.35% |
| 2014-12-31 | $-15.86M | $9.84M | (m) | $13.66M | (m) | -161.14% |
| 2014-09-30 | $-15.53M | $9.37M | (m) | $13.14M | (m) | -165.70% |
| 2014-06-30 | $-10.65M | $14.81M | (m) | $13.61M | (m) | -71.91% |
| 2014-03-31 | $-9.81M | $15.42M | (m) | $13.44M | (m) | -63.65% |
| 2013-12-31 | $-9.42M | $15.00M | (m) | $12.93M | (m) | -62.77% |
| 2013-09-30 | $-18.37M | $15.16M | (m) | $12.67M | (m) | -121.11% |
| 2013-06-30 | $-23.46M | $8.54M | (m) | $11.54M | (m) | -274.67% |
| 2013-03-31 | $-25.18M | $7.49M | (m) | $12.88M | (m) | -336.27% |
| 2012-12-31 | $-18.62M | $16.97M | (m) | $15.49M | (m) | -109.71% |
| 2012-09-30 | $2.38M | $29.37M | (m) | $17.23M | (m) | 8.09% |
| 2012-06-30 | $2.52M | $28.94M | (m) | $17.23M | (m) | 8.71% |
| 2012-03-31 | $329.50K | $24.99M | (m) | $15.88M | (m) | 1.32% |
| 2011-12-31 | $-7.20M | $14.76M | (m) | $13.69M | (m) | -48.79% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-5.64M | $16.00M | (m) | $11.37M | (m) | -35.24% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-10.04M | $8.59M | (m) | $9.93M | (m) | -116.94% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |